Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Phase 2

Withdrawn

Conditions: Systemic Lupus Erythematosus

Interventions: Procedure: Plasmapheresis
Procedure: Leukapheresis
Drug: Rabbit anti-thymocyte globulin
Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
Procedure: Autologous CD34+HPC transplantation (HSCT)
Drug: Methylprednisolone
Drug: Growth colony stimulating factor (G-CSF)
Drug: Corticosteroids
Drug: Mycophenolate mofetil
Drug: Azathioprine
Drug: Intravenous immunoglobulin
Drug: Methotrexate
Drug: Rituximab
Drug: Leflunomide

First Posted Date: 2005-09-30

Last Posted Date: 2013-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00230035

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
UCSD, Thornton Hospital, La Jolla, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids

Phase 3

Completed

Conditions: Post-Extubation Laryngeal Edema

First Posted Date: 2005-09-20

Last Posted Date: 2005-09-20

Lead Sponsor: University Hospital, Limoges

Target Recruit Count: 670

Registration Number: NCT00199576

Locations: 🇫🇷
Service de Réanimation - CH de Brive, Brive, France
🇫🇷
Service de Réanimation - CH de Chartres, Chartres, France
🇫🇷
Service de Réanimation - CH de Dreux, Dreux, France

and more 12 locations

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Phase 3

Completed

Conditions: Heart Diseases
Heart Transplantation

Interventions: Drug: Tacrolimus
Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2005-09-12

Last Posted Date: 2017-06-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 111

Registration Number: NCT00157014

Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

Not Applicable

Terminated

Conditions: Inflammatory Bowel Disease (IBD)

First Posted Date: 2005-09-09

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 40

Registration Number: NCT00152620

Locations: 🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States

Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients

Phase 4

Completed

Conditions: Liver Transplant

Interventions: Drug: Cyclosporine A
Drug: Tacrolimus
Drug: Basiliximab
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2005-09-08

Last Posted Date: 2011-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 171

Registration Number: NCT00149994

Locations: 🇨🇭
Novartis, Basel, Switzerland

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Phase 2

Completed

Conditions: Graft Vs Host Disease

Interventions: Drug: Prochymal® - 2 Million cells/kg
Drug: Prochymal®- 8 Million cells/kg
Drug: Methylprednisolone
Drug: Prednisone
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2005-08-29

Last Posted Date: 2022-01-31

Lead Sponsor: Mesoblast, Inc.

Target Recruit Count: 32

Registration Number: NCT00136903

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
St. Francis Hospital, Indianapolis, Indiana, United States
🇺🇸
New York Medical College, Valhalla, New York, United States

and more 6 locations

Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome

Phase 2

Completed

Conditions: Hantavirus Infections

Interventions: Drug: Placebo
Drug: Methylprednisolone

First Posted Date: 2005-08-09

Last Posted Date: 2014-12-24

Lead Sponsor: University of New Mexico

Target Recruit Count: 66

Registration Number: NCT00128180

Locations: 🇨🇱
Facultad de Medicina Clinica Alemana- Universidad del Desarrollo, Santiago, Chile

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Sarcoma
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2005-06-03

Last Posted Date: 2013-07-18

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 10

Registration Number: NCT00112645

Locations: 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cisplatin
Drug: etoposide
Drug: gemcitabine
Drug: methylprednisolone

First Posted Date: 2005-05-04

Last Posted Date: 2014-10-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 34

Registration Number: NCT00109928

Locations: 🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States

and more 73 locations

Campath-1H + FK506 and Methylprednisolone for GVHD

Phase 2

Completed

Conditions: Breast Cancer
Chronic Myeloproliferative Disorders
Gestational Trophoblastic Tumor
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Neuroblastoma

First Posted Date: 2005-05-04

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT00109993

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Mt. Sinai Medical Center, New York, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy